Compared to CFTR addition, CRISPR-based CFTR editing offers distinct advantages for CF gene therapy—it has the potential to restore regulated CFTR expression under endogenous control in functionally relevant cell targets and may eliminate the need for repeat dosing if the airway stem/progenitor cells are effectively targeted. This evidence concerns the gene CFTR and cystic fibrosis.